{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T05:53:02Z","timestamp":1668491582049},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.1001\/jamaneurol.2022.2311","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:31:50Z","timestamp":1663601510000},"page":"1100","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab in Newly Diagnosed Generalized Myasthenia Gravis"],"prefix":"10.1001","volume":"79","author":[{"given":"Miguel","family":"Chuquilin","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Barohn","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Missouri School of Medicine, Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"12","key":"ned220011r1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"ned220011r2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"ned220011r3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"ned220011r4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.v56.2","article-title":"Rituximab treatment of myasthenia gravis: a systematic review.","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"4","key":"ned220011r5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review.","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ned220011r6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis.","volume":"85","author":"Li","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"6","key":"ned220011r7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis.","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ned220011r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577528","article-title":"Low-dose rituximab treatment for new-onset generalized myasthenia gravis.","volume":"354","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"ned220011r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577383","article-title":"Low-dose rituximab lowers serum exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.","volume":"348","author":"Zhong","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"8","key":"ned220011r10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.","volume":"269","author":"Du","year":"2022","journal-title":"J Neurol"},{"issue":"3","key":"ned220011r11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.v61.3","article-title":"Low-dose rituximab every 6?months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.","volume":"61","author":"Lu","year":"2020","journal-title":"Muscle Nerve"},{"issue":"2","key":"ned220011r12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","article-title":"Memory B cells predict relapse in rituximab-treated myasthenia gravis.","volume":"18","author":"Ruetsch-Chelli","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"4","key":"ned220011r13","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study.","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"ned220011r14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis.","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"ned220011r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial.","author":"Piehl","journal-title":"JAMA Neurol"},{"key":"ned220011r16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"3","key":"ned220011r17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases.","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"3","key":"ned220011r18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights.","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2796553\/jamaneurology_chuquilin_2022_ed_220011_1667929396.40264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:09:33Z","timestamp":1668442173000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2796553"}},"subtitle":["A New Treatment Paradigm?"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.2311","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}